We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA Rejects Physician Notification in Biosimilar Substitution Showdown
GPhA Rejects Physician Notification in Biosimilar Substitution Showdown
Jumping back into the biosimilar substitution debate, GPhA is saying it prefers doctors not be notified when a pharmacist substitutes a biosimilar for a name-brand biologic, and it supports legislative language that would implement that approach in states throughout the U.S.